Aspirin and colorectal cancer prevention. Exploring the platelet hypothesis of its mechanism of actio

Conditions: We will perform this clinical study to address the hypothesis that low-dose aspirin given once daily is acting primarily by selectively acetylating platelet COX-1 and suppressing its activity throughout the 24-hour dosing interval.
Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Registration Number: EUCTR2013-004269-15-ES

Lead Sponsor: Insituto Aragonés de Ciencias de la Salud

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Authorised-recruitment may be ongoing or finished

Sex: All

Target Recruitment: Not specified

Inclusion Criteria

1.Patients should be ? 18 years and no older than 69
2.Patients should have an indication for screening colonoscopy (patients > 50 years or personal or familiar history of CCR or adenomas )
a.First degree relative of patient with CRC.
b.Personal history of adenomas.
c.People older than 50 and FOBT positive
3.Routine hematological and biochemical parameters within the normal range
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 40
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 40

Exclusion Criteria

1.Allergy to aspirin or other NSAIDs.
2.Previous use of aspirin, NSAIDS, antiplatelet agents, corticosteroids or misoprostol in the previous 15 days and/or anticipated need for these drugs during the study period.
3.Peptic ulcer history or any other gastrointestinal disease that could be considered a contraindication for aspirin use without the concomitant use of a proton-pump inhibitor
4.Subjects with a bleeding disorder
5.Malignancies, excluding CRC, diagnosed in the previous 5 years
6.Serious comorbid condition, including pulmonary, cardiac, liver or kidney diseases, cigarette smoking, history of drug or alcohol abuse
7.Pregnant women or breast feeding